

INDEX

- accessory ostia, 2
- adenosine triphosphate (ATP), for ciliary motility, 20
- adhesiolysis, 93–94
- adrenergic compounds, fallopian tube motility and, 6
- age, as factor in tubal factor infertility (TFI), 91
- AIJ. *See* ampullary-isthmic junction
- AMH. *See* anti-Müllerian hormone
- ampullary-isthmic junction (AIJ), 18
 - fertilization within, 22
- angiotensin II, in CBF frequency regulation, 20
- animal models
 - Chlamydia trachomatis* in, 33
 - tobacco use and, effects of, 23–24
- anti-D immunoglobulin, 64
- anti-Müllerian hormone (AMH), 1–2
- aplasia, 2
- apparent proximal tubal occlusion, 46
- assisted reproduction
 - coculture and, 8–14
 - sequential culture and, 8
- ATP. *See* adenosine triphosphate
- bacteria. *See* Chlamydia trachomatis
- bacterial vaginosis, 104
- balloon tuboplasty, 50
- bipolar tubal disease, surgical treatment for, 87
- breast cancer, tubal sterilization and, 118–119
- CBF. *See* ciliary beat frequency (CBF), regulation of
- cell-mediated immune (CMI) responses, 35
- Chlamydia trachomatis*, 24, 30–35
 - animal models for, 33
 - CBF regulation and, 24
 - cytokine response to, 34
 - GM-CSF and, 34
 - development cycle of, 30
 - ectopic pregnancy and, 33
 - in female genital tract, 33–35
 - heat shock proteins and, 35
 - HLA systems immune responses and, 33–34
 - lab diagnosis for, 30–32
 - with ELISA, 32
 - with NAATs, 30
 - pelvic adhesions from, 33
 - PID and, 33, 54–55
 - prevalence rates for, 30, 33
 - screening for, 32–33, 35
 - CMI responses in, 35
 - in presurgery assessment, 89
 - tubal disease from, 103–104
- chromolaparoscopy. *See* dye studies, in fallopian tube patency testing
- chronic salpingitis, 22
- ciliary beat frequency (CBF), regulation of, 20–21
 - angiotensin II in, 20
 - ATP in, 20
 - chlamydia infection and, 24
 - endometriosis and, 23
 - estrogen levels and, 20–21
 - after ovulation, 20–21
 - progesterone and, 20–21
 - prostaglandins and, 21
 - tobacco use as negative influence on, 23–24
- ciliary motility, in fallopian tubes, 19–20
 - ATP as requirement for, 20
 - immotile cilia syndrome and, 19
 - Kartagener’s syndrome and, 19
 - PCD and, 19–20
 - gene protein targets for, 20
 - as heterogeneous disorder, 19–20
- ciprofloxacin, 38
- citrovorum, 63
- CMI. *See* cell-mediated immune responses
- COCs. *See* combined oral contraceptives
- coculture, assisted reproduction and, 8–14
 - efficacy of, 9–10
 - with epithelial cells, 9–10
 - oviductal, 8, 9
 - disadvantages with, 9
 - as helper cells, 9
 - in mice models, 12–13
 - microenvironment simulation, 10–12
 - obstacles with, 13
 - without oviductal cells, 12–13
 - positive conditioning mechanisms for, 12
 - randomized trials for, 9
 - as study model, 13–14
 - sequential culture and, 10
 - somatic cells with, 9
 - endometrial, 9

- coculture, assisted reproduction and (*cont.*)
 - granulosa cells, 9
 - Vero cells, 9
- combined oral contraceptives (COCs), 113
- congenital diverticula, 2
- Crohn's disease, TFI and, 39–40
- culdcentesis, for diagnosis of ectopic pregnancy, 60
- culdoscopy, for fallopian tube patency testing, 74
- cytokines
 - C. trachomatis* and, 34
 - GM-CSF, 10
 - C. trachomatis* and, response to, 34
 - in oviductal microenvironment simulation, 11
- Deichert, Ulrich, 70
- diethylstilbestrol (DES), ectopic pregnancy
 - from exposure to, 56
- distal occlusion, 46
- distal tubal disease, surgical treatment for, 86–87
 - pregnancy rates with, 86–87
- distal tube surgery, 96–97
 - fimbrioplasty, 96
 - pregnancy rates after, 97
 - salpingostomy, 96–97
- dye studies, in fallopian tube patency testing, 73–74
- ectopic pregnancies, 65
 - from *C. trachomatis*, 33, 54–55
 - clinical presentation of, 57–58
 - from physical examination, 57–58
 - symptoms in, 57
 - complications of, 64–65
 - intrauterine pregnancy as, 64–65
 - persistent trophoblastic tissue, 64
 - diagnosis of, 58–60
 - through biochemical markers, 58–59
 - through imaging techniques, 59–60
 - incidence rates for, 53
 - from IVF, 51, 55–56
 - IVF and, 51
 - LNG-IUS and, 55
 - from *N. gonorrhoeae*, pathophysiology of, as recurrent, 65
 - risk factors for, 53–56
 - age at first intercourse as, 56
 - DES exposure as, 56
 - endometriosis as, 56
 - history of infertility as, 55–56
 - IUD use, 55
 - multiple sexual partners as, 56
 - PID as, 54–55
 - previous ectopic pregnancies as, 55
 - vaginal douching as, 56
 - after surgical treatment of TFI, 92
 - TFI as risk factor for, 55–56, 64–65
 - tobacco use and, 23, 56
 - treatment for, 60–64
 - with anti-D immunoglobulin, 64
 - expectant management in, 63–64
 - through medical agents, 62–63
 - with methotrexate, 62–63
 - through surgery, 60–62
 - from tubal sterilization, 117–118
- ELISA. *See* enzyme linked immunosorbent assay
- embryo development, oviduct and, 8
- endometrial cells, in coculture studies, 9
- endometriosis, 22–24
 - CBF and, 23
 - ectopic pregnancies and, 56
 - human sperm as factor in, 23
 - macromolecular ovum capture inhibitors and, 23
 - peritoneal macrophage levels and, 22–23
 - true cornual tubal occlusion and, 47–48
 - tubal disease from, 104
- endometrium, tubal disease and, IVF and, 107
 - C. trachomatis* and, 107
 - during IVF-ET, 107
- enzyme linked immunosorbent assay (ELISA), 32
- episodic contraction, 19
- epithelial cells, in coculture environments, 9–10
- essure sterilization, 115
- estrogen
 - CBF regulation and, 20–21
 - fallopian tube motility and, 5–6
- fallopian tube(s). *See also* fallopian tube patency, testing for; tubal factor infertility; tubal transport
 - accessory ostia, 2
 - anatomy of, 2–3
 - aplasia,
 - blood supply for, 4
 - ciliary motility in, 19–20
 - immotile cilia syndrome and, 19
 - Kartagener's syndrome and, 19
 - PCD and, 19–20
 - congenital diverticula, 2
 - development of, 2–6
 - congenital anomalies in, 2
 - embryology in, 2
 - hypoplasia, 2
 - motility in, 5–6
 - adrenergic innervation and, 6
 - estrogen as stimulant for, 5–6
 - peristaltic contraction for, 5
 - progesterone as inhibitor for, 5–6
 - prostaglandins and, 6
 - from Müllerian ducts, 3
 - muscular contractility in, 18–19

- episodic contraction, 19
- hormone receptors and, 19
- sustained tonic contractions, 18–19
- PTO and, 46–48
- structure of, 3–4
 - ampullary part, 3–4
 - histological organization in, 4
 - infundibulum, 4
- tobacco use and, as negative developmental influence, 23
- CBF regulation and, 23–24
- ectopic pregnancy and, 23
- GIFT and, 24
- tubal development and, 23
- tubal mucosa in, 4–5
 - cell form in, 4–5
 - function of, 5
- uterine tube cycle for, 5
 - cell change during, 5
- fallopian tube patency, testing for, 70–80
 - chlamydial serology in, 79
 - with HSS, 79
 - concordance between techniques for, 78–79
 - with culdoscopy, 74
 - with dye studies, 73–74
 - with falloposcopy, 79
 - history of, 70
 - Rubin test, 70
 - infection risks from, 72
 - with laparoscopy, 73–74
 - necessity of, 70–71
 - pain from, 72
 - with salpingoscopy, 79
 - technique selection for, 73
 - therapeutic tubal flushing, 74–77
 - contrast mediums for, 75
 - HyCoSy, 75–77
 - timing factors for, 71–72
 - with X-ray HSG, 74
- falloposcopy
 - in fallopian tube patency testing, 79
 - in presurgical assessment, for TFI, 90
- FDP. *See* fibrin degradation products
- female reproductive tract
 - AMH, 1–2
 - development of, 1–2
 - fallopian tube in, 2–6
- fetal age, 2
- fibrin degradation products (FDP), 40
- Filshie clip sterilization, 85, 115
 - proximal microsurgical reanastomosis for, 94
- fimbrioplasty, 96
- Fitz-Hugh-Curtis syndrome, 37
- follicle-stimulating hormone (FSH), 90
 - in IVF stimulation regimens, 107–108
- FSH. *See* follicle-stimulating hormone
- gamete intrafallopian transfer (GIFT), 24
- GIFT. *See* gamete intrafallopian transfer
- GM-CSF. *See* granulocyte-macrophage colony-stimulating factor
- GnRH agonists. *See* gonadotropin-releasing hormone (GnRH) agonists, in IVF stimulation regimens
- gonadal differentiation, 1
- gonadotropin-releasing hormone (GnRH) agonists, in IVF stimulation regimens, 108
- granulocyte-macrophage colony-stimulating factor (GM-CSF), 10
 - C. trachomatis* and, response to, 34
 - in oviductal microenvironment simulation, 11
- granulosa cells, 9
- hCG. *See* human chorionic gonadotropin
- heat shock proteins, 35
- HLA systems, *C. trachomatis* and, 33–34
- HSG findings. *See* hysterosalpingographic testing
- HSS. *See* hysterosalpingo scintillography
- Hulka-Clemens Spring Clip sterilization, 115
- human chorionic gonadotropin (hCG), 58–59
- HyCoSy testing. *See* hysterosalpingo-contrast sonography
- hypoplasia, 2
- hysterectomy, tubal sterilization and, 118
- hysterosalpingo-contrast sonography (HyCoSy), 48
 - in fallopian tube patency testing, 75–77
 - advantages and disadvantages for, 76–77
 - contrast media for, 75–76
- hysterosalpingo scintillography (HSS), 79
- hysterosalpingographic (HSG) testing
 - for PTO, 46, 48
 - for TFI, in presurgery assessment, 89
 - X-ray, for fallopian tube patency, 74
- hysteroscopic sterilization, 114–115
- iatrogenic tubal sterilization, 84. *See also* Filshie clip sterilization; sterilization reversal, in women
- IGF-1. *See* insulin-like growth factor-1
- immotile cilia syndrome, 19
- in vitro fertilization (IVF). *See also* tubal disease, IVF and
 - ectopic pregnancies and, 51, 55–56
 - after PTO, 51, 52
 - surgical treatment and, 87–88
 - as alternative to, 92–93
 - tubal disease and, 103–109
 - causes of, 103–105
 - endometrium and, effect on, 107
 - oocyte collection, 108
 - outcomes for, 105–106

- in vitro fertilization (IVF) (*cont.*)
 - ovarian response and, postsurgery, 106–107
 - stimulation regimens for, 107–108
 - success rates after, age as factor in, 108–109
- in vitro fertilization-embryo transfer (IVF-ET), 105–106
 - endometrium and, effects on, 107
- insulin-like growth factor-1 (IGF-1), 10
 - in oviductal microenvironment simulation, 11
- intrauterine contraceptive devices (IUCDs), 113
- intrauterine devices (IUDs), ectopic pregnancies and, 55
 - LNG-IUS and, 55
- IUCDs. *See* intrauterine contraceptive devices
- IUDs. *See* intrauterine devices
- IVF-ET. *See* in vitro fertilization-embryo transfer
- Kartagener’s syndrome, 19
- laparoscopy
 - complications from, 91–92
 - for ectopic pregnancy
 - in diagnosis of, 60
 - in surgical treatment of, laparotomy v., 61
 - in fallopian tube patency testing, 73–74
 - for PTO, 48–49
 - in reconstructive surgery, for fertility, 95–96
 - techniques for, 96
 - for surgical treatment assessment, 89–90
 - tubal sterilization with, 114
- laparotomy
 - complications from, 91–92
 - for ectopic pregnancy, 61
- leukemia inhibitory factor (LIF), 10
 - in oviductal early embryo development, 11
- levonorgestrel intrauterine system (LNG-IUS), 55
- LIF. *See* leukemia inhibitory factor
- LNG-IUS. *See* levonorgestrel intrauterine system
- male reproductive tract
 - brain and hypothalamic sexual identity acquisition, 1
 - gonadal differentiation for, 1
 - sex chromosomes in, 1
- mesoalpingeal muscle, ovum transport and, 21
- metalloproteinases (MMPs), 40
- methotrexate, for ectopic pregnancy, 62–63
 - with citrovorum, 63
 - salpingostomy v., 63
- mice models, in coculture oviductal development, 12–13
- midtubal occlusion, 46
- mifepristone, 62
- “milking technique,” 62
- MMPs. *See* metalloproteinases
- Müllerian ducts, 3
 - sexual identity acquisition and, as inhibiting substance, 1
 - AMH and, 1–2
- muscular contractility, in fallopian tubes, 18–19
 - episodic contraction, 19
 - hormone receptors and, 19
 - sustained tonic contractions, 18–19
 - in AIJ, 18
 - in UTJ, 18
- NAATs. *See* nucleic acid amplification tests
- Neisseria gonorrhoeae*, 24, 36–38
 - antigenic adaptability for, 37–38
 - ectopic pregnancies from, Fitz-Hugh-Curtis syndrome from, 37
 - lab diagnosis for, 38
 - PID from, 37
 - prevalence rates for, 36–37
 - primary infection sites for, 37
 - symptoms for, 37
 - treatment for, 38
 - tubal disease from, 104
- nucleic acid amplification tests (NAATs), 30
- occlusion. *See* tubal sterilization
- ofloxacin, 38
- oocyte collection, 108
- ovarian cancer, tubal sterilization and, 118–119
- ovarian reserves, 90–91
- oviduct, early embryo development and, 8
 - coculture, 8, 9
 - disadvantages with, 9
 - as helper cells, 9
 - in mice models, 12–13
 - without oviductal cells, 12–13
 - positive conditioning mechanisms for, 12
 - randomized trials for, 9
 - as study model, 13–14
 - microenvironment simulation, 10–12
 - GM-CSF in, 11
 - IGF-1 in, 11
 - LIF in, 11
 - TGFβ-1 in, 11
- ovum capture inhibitors, 23
- ovum transport, 21–22
 - chronic salpingitis and, 22
 - clinical observations of, 22
 - mesoalpingeal muscle and, 21
 - transit time for, 22
- PAPP-A. *See* pregnancy associated plasma protein-A
- PCD. *See* primary ciliary dyskinesia
- pelvic actinomycosis, 104
- pelvic adhesions, 33
- pelvic inflammatory disease (PID)

- C. trachomatis* and, 33, 54–55
- ectopic pregnancy and, 54–55
- from *N. gonorrhoeae*, 37, 54–55
- TFI from, 40
 - extratubal adhesions and, 40–41
 - FDP and, 40
 - fibrin matrix formation and, 40
 - MMPs and, 40
 - peritoneum insult, 40
 - TIMPs and, 40
- true cornual tubal occlusion and, 47–48
- tubal disease from, 103
- pelvic inflammatory disease (PID), from *C. trachomatis*, 33
- persistent trophoblastic tissue, 64
- PID. *See* pelvic inflammatory disease (PID), from *C. trachomatis*
- Pomeroy tubal ligation, 115
- pregnancy associated plasma protein-A (PAPP-A), 59
- primary ciliary dyskinesia (PCD), 19–20
 - gene protein targets for, 20
 - as heterogeneous disorder, 19–20
- progesterone
 - as biochemical marker, in ectopic pregnancy, 59
 - CBF regulation and, 20–21
 - fallopian tube motility inhibition from, 5–6
- prostaglandins
 - CBF regulation and, 21
 - fallopian tube motility and, 6
- proteins
 - gene target, in PCD, 20
 - heat shock, 35
- proximal microsurgical reanastomosis, 94–95
 - for Filshie clip sterilization, 94
 - postoperative care for, 95
 - technique for, 94–95
- proximal tubal obstruction, surgical treatment for, 86
- proximal tubal occlusion (PTO), 46–52
 - apparent, 46
 - diagnostic tests for, 48–49
 - HSG, 48
 - HyCoSy, 48
 - laparoscopy, 48–49
 - STC, 48
 - false diagnosis of, 46
 - HSG findings in, 46
 - histopathology of, 46–48
 - IVF and, 51, 52
 - management of, 49–51
 - with balloon tuboplasty, 50
 - with hormonal suppression, 49
 - pregnancy rates after, 51
 - radiological approaches to, 49–50
 - with surgery, 50–51
 - tubo-cornual anastomosis in, 51
 - true cornual, 47–48
 - endometriosis and, 47–48
 - PID and, 47–48
 - SIN and, 47
- randomized trials, for oviductal cell coculture, 9
- reconstructive surgery, for fertility, 93–98
 - with adhesiolysis, 93–94
 - with distal tube surgery, 96–97
 - fimbrioplasty, 96
 - pregnancy rates after, 97
 - salpingostomy, 96–97
 - laparoscopic reversal of sterilization, 95–96
 - techniques for, 96
 - with proximal microsurgical reanastomosis, 94–95
 - for Filshie clip sterilization, 94
 - postoperative care for, 95
 - technique for, 94–95
 - with salpingectomy, 97–98
 - tubal cannulation techniques in, 98
- reproductive tract, 1–2
 - brain and hypothalamic sexual identity acquisition, 1
 - Müllerian-inhibiting substance, 1
- female
 - AMH in, 1–2
 - development of, 1–2
 - gonadal differentiation in, 1
 - sex chromosomes and, 1
- RU486. *See* mifepristone
- Rubin test, for fallopian tube patency, 70
 - image intensifier for, 70
- salpingectomy
 - for ectopic pregnancy, 61
 - as reconstructive surgery for fertility, 97–98
- salpingitis isthmica nodosa (SIN), 47
 - tubal disease from, 105
- salpingoscopy, in fallopian tube patency testing, 79
- salpingostomy
 - for ectopic pregnancy, 61
 - methotrexate treatment v., 63
 - as reconstructive, for fertility, 96–97
 - selective tubal catheterization (STC), 48
- semen analysis, 91
- sequential culture, assisted reproduction and, 8
 - coculture and, 10
 - GM-CSF supplementation in, 10
 - IGF-1 supplementation in, 10
 - rationale of, 10
- sexual identity acquisition
 - brain and hypothalamic influences, 1
 - Müllerian-inhibiting substance for, 1
 - AMH and, 1–2

- sexually transmitted infections (STIs)
 - C. trachomatis*, 24, 30–35
 - animal models for, 33
 - CBF regulation and, 24
 - cytokine response to, 34
 - development cycle of, 30
 - ectopic pregnancy and, 33
 - in female genital tract, 33–35
 - heat shock proteins and, 35
 - HLA systems immune responses and, 33–34
 - lab diagnosis for, 30–32
 - pelvic adhesions from, 33
 - PID and, 33
 - prevalence rates for, 30, 33
 - screening for, 32–33, 35
 - N. gonorrhoeae*, 24, 36–38
 - antigenic adaptability for, 37–38
 - Fitz-Hugh-Curtis syndrome from, 37
 - lab diagnosis for, 38
 - PID from, 37
 - prevalence rates for, 36–37
 - primary infection sites for, 37
 - symptoms for, 37
 - treatment for, 38
- Silastic ring sterilization, 115
- SIN. *See* salpingitis isthmica nodosa
- smoking. *See* tobacco use
- spectinomycin, 38
- sperm, endometriosis and, as factor in, 23
- STC. *See* selective tubal catheterization
- Steptoe, Patrick, 70
- sterilization reversal, in women, 84–85, 119
 - for Filshie clip sterilization, 85
 - pregnancy factors after, 85
- STIs. *See* sexually transmitted infections
- surgery, as treatment. *See also* laparoscopy;
reconstructive surgery, for fertility;
tubal damage, surgical treatment for
 - for ectopic pregnancy, 60–62
 - laparoscopy v. laparotomy, 61
 - “milking technique” in, 62
 - salpingectomy v. salpingostomy, 61
- for PTO, 50–51
- as reconstructive, 93–98
 - with adhesiolysis, 93–94
 - with distal tube surgery, 96–97
 - laparoscopic reversal of sterilization, 95–96
 - with proximal microsurgical reanastomosis, 94–95
 - with salpingectomy, 97–98
- tubal cannulation techniques in, 98
- for TFI, 84–98
 - age of female as factor in, 91
 - chlamydia screening and, 89
 - complications from, 91–92
 - counseling for, 91–92
 - ectopic pregnancy as complication of, 92
 - FSH levels and, 90
 - HSG testing and, 89
 - imaging techniques in assessment of, 89
 - indications for, 84
 - IVF as alternative to, 92–93
 - for IVF treatment, 87–88
 - menstrual history in assessment of, 91
 - ovarian reserves and, 90–91
 - pregnancy rates after, 85
 - preoperative assessment for, 88–91
 - principles and technique for, 93
 - as reconstructive, 93–98
 - semen analysis in assessment of, 91
 - for sterilization reversal, in women, 84–85
 - for tubal damage, 85–87
 - tubal disease from, 105
- sustained tonic contractions, 18–19
 - in AIJ, 18
 - in UTJ, 18
- TB. *See* tuberculosis
- TFI. *See* tubal factor infertility
- TGFβ-1. *See* transforming growth factor β-1
- TIMPs. *See* tissue inhibitors of metalloproteinases
- tissue, pelvic inflammatory disease (PID), TFI from, TIMPs and,
- tissue inhibitors of metalloproteinases (TIMPs), 40
- tobacco use, 23–24
 - CBF regulation and, 23–24
 - ectopic pregnancy and, 23, 56
 - fallopian tube development and, 23
 - GIFT and, 24
- transforming growth factor β-1 (TGFβ-1), in oviductal environment simulation, 11
- true cornual tubal occlusion, 47–48
 - endometriosis and, 47–48
 - PID and, 47–48
 - SIN and, 47
- tubal cannulation techniques, for fertility, 98
- tubal catheterization, complications from, 91–92
- tubal damage, surgical treatment for, 85–87
 - from bipolar tubal disease, 87
 - from distal tubal disease, 86–87
 - from proximal tubal obstruction, 86
 - from unilateral proximal disease, 87
- tubal disease, IVF and, 103–109
 - causes of, 103–105
 - bacterial vaginosis as, 104
 - C. trachomatis* as, 103–104
 - congenital abnormalities as, 105
 - endometriosis as, 104
 - infection as, 103–104
 - N. gonorrhoeae* as, 104
 - pelvic actinomycosis as, 104
 - pelvic TB as, 104
 - PID as, 103

- SIN as, 105
 - surgery as, 105
 - endometrium and, effect on, 107
 - C. trachomatis* and, 107
 - during IVF-ET, 107
 - oocyte collection, 108
 - outcomes for, 105–106
 - with hydrosalpinges, 106
 - for IVF-ET, 105–106
 - ovarian response and, postsurgery, 106–107
 - stimulation regimens for, 107–108
 - with FSH, 107–108
 - with GnRH agonists, 108
 - success rates after, age as factor in, 108–109
 - tubal factor infertility (TFI)
 - C. trachomatis* and, 24, 30–35
 - animal models for, 33
 - CBF regulation and, 24
 - cytokine response to, 34
 - development cycle of, 30
 - ectopic pregnancy and, 33
 - in female genital tract, 33–35
 - heat shock proteins and, 35
 - HLA systems immune responses and, 33–34
 - lab diagnosis for, 30–32
 - pelvic adhesions from, 33
 - PID and, 33
 - prevalence rates for, 30, 33
 - screening for, 32–33, 35
 - Crohn's disease and, 39–40
 - from distal tubal disease, 86–87
 - ectopic pregnancies and, patient history as factor for, 55–56, 64–65
 - N. gonorrhoeae* and, 24, 36–38
 - antigenic adaptability for, 37–38
 - Fitz-Hugh-Curtis syndrome from, 37
 - lab diagnosis for, 38
 - PID from, 37
 - prevalence rates for, 36–37
 - primary infection sites for, 37
 - symptoms for, 37
 - treatment for, 38
 - PID and, 40
 - extratubal adhesions and, 40–41
 - FDP and, 40
 - fibrin matrix formation and, 40
 - MMPs and, 40
 - peritoneum insult, 40
 - TIMPs and, 40
 - from proximal tubal obstruction, 86
 - serological markers for, 35
 - surgery as treatment for, 84–98
 - age of female as factor in, 91
 - chlamydia screening and, 89
 - complications from, 91–92
 - counseling for, 91–92
 - ectopic pregnancy as complication of, 92
 - FSH levels and, 90
 - indications for, 84
 - IVF as alternative to, 92–93
 - for IVF treatment, 87–88
 - menstrual history in assessment of, 91
 - ovarian reserves and, 90–91
 - pregnancy rates after, 85
 - preoperative assessment for, 88–91
 - principles and technique for, 93
 - as reconstructive, 93–98
 - semen analysis in assessment of, 91
 - for sterilization reversal, in women, 84–85
 - for tubal damage, 85–87
- TB and, 38–39
 - genome matching for, 39
 - lesion localization for, 39
 - management of, 39
 - symptoms for, 39
- tubal fulguration with diathermy, 115
- tubal occlusion
 - distal, 46
 - midtubal, 46
 - PTO, 46–52
 - apparent, 46
 - diagnostic tests for, 48–49
 - false diagnosis of, 46
 - histopathology of, 46–48
 - IVF and, 51, 52
 - management of, 49–51
 - true cornual, 47–48
- tubal reanastomosis, 119. *See also* sterilization reversal, in women
- tubal sterilization, 113–119
 - COC use and, 113
 - complications of, 116–119
 - ectopic pregnancy as, 117–118
 - menstrual disturbances as, 118
 - personal regret as, 116
 - procedural failure as, 116–117
 - long-term outcomes from, 118–119
 - breast cancer as, 118–119
 - hysterectomy risk as, 118
 - ovarian cancer as, 118–119
 - methods of, 114–116
 - essure, 115
 - with Filshie clips, 85, 115
 - with Hulka-Clemens Spring Clips, 115
 - hysteroscopic, 114–115
 - laparoscopic, 114
 - Pomeroy tubal ligation, 115
 - with Silastic rings, 115
 - tubal fulguration with diathermy, 115
 - prevalence rates for, 113
 - rationale and objectives for, 113–114
 - reversal of, 84–85, 119
 - for Filshie clip sterilization, 85
 - pregnancy factors after, 85

- tubal transport. *See also* ciliary beat frequency (CBF), regulation of; ciliary motility, in fallopian tubes; muscular contractility, in fallopian tubes; ovum transport
- pathophysiology of, 22–24
 - C. trachomatis* and, 24, 30–35
 - endometriosis as, 22–24
 - fallopian cilia and, 24
 - microorganisms and, 24
 - N. gonorrhoeae* and, 24
 - tobacco use and, 23–24
- physiology of, 18–22
 - CBF regulation in, 20–21
 - ciliary motility in, 19–20
 - muscular contractility in, 18–19
 - ovum transport in, 21–22
- tuberculosis (TB)
 - TFI and, 38–39
 - genome matching for, 39
 - lesion localization for, 39
 - management of, 39
 - symptoms for, 39
- tubal disease from, 104
- ultrasound, for diagnosis of ectopic pregnancy, 59–60
 - HyCoSy, 48
 - in fallopian tube patency testing, 75–77
- unilateral proximal disease, surgical treatment for, 87
- uterotubal junction (UTJ), 18
- UTJ. *See* uterotubal junction
- vaginal douching, as risk for ectopic pregnancy, 56
- Vero cells, 9
- X-ray HSG testing, for fallopian tube patency, 74